• 1
    Jonsson R, Moen K, Vestrheim D, Szodoray P. Current issues in Sjögren's syndrome. Oral Dis 2002;8: 13040.
  • 2
    Jonsson R, Brokstad KA. Sjögren's syndrome. In: AustenKF, FrankMM, AtkinsonJP, CantorHI, eds. Samter's Immunologic Diseases: A Textbook of Rheumatology, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2001: 495504.
  • 3
    Garcic-Carrasco M, Font J, Filella X et al. Circulating levels of Th1/Th2 cytokines in patients with primary Sjogren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001;19: 4115.
  • 4
    Perrier S, Serre AF, Dubost JJ et al. Increased serum levels of interleukin 10 in Sjogren's syndrome; correlation with increased IgG1. J Rheumatol 2000;27: 9359.
  • 5
    Sfriso P, Ostuni P, Botsios C et al. Serum and salivary neopterin and interferon-gamma in primary Sjogren's syndrome. Correlation with clinical, laboratory and histopathologic features. Scand J Rheumatol 2003;32: 748.
  • 6
    Anaya JM, Correa PA, Herrera M, Eskdale J, Gallagher G. Interleukin 10 (IL-10) influences autoimmune response in primary Sjogren's syndrome and is linked to IL-10 gene polymorphism. J Rheumatol 2002;29: 18746.
  • 7
    Spadaro A, Rinaldi T, Riccieri V, Taccari E, Valesini G. Interleukin-13 in autoimmune rheumatic diseases: relationship with the autoantibody profile. Clin Exp Rheumatol 2002;20: 2136.
  • 8
    Kohriyama K, Katayama Y. Disproportion of helper T cell subsets in peripheral blood of patients with primary Sjogren's syndrome. Autoimmunity 2000;32: 6772.
  • 9
    Bowman SJ, Pillemer S, Jonsson R et al. Contributors to and participants at the workshop. Revisiting Sjogren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. Rheumatol (Oxford) 2001;40: 11808.
  • 10
    Bowman SJ. Collaborative research into outcome measures in Sjogren's syndrome. Update on disease assessment. Scand J Rheumatol Suppl 2002;116: 237.
  • 11
    Yadav D, Sarvetnick N. Cytokines and autoimmunity: redundancy defines their complex nature. Curr Opin Immunol 2003;15: 697703.
  • 12
    Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61: 5548.
  • 13
    Willeke P, Schotte H, Schluter B et al. Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjogren's syndrome. Ann Rheum Dis 2003;62: 35962.
  • 14
    Spadaro A, Scrivo R, Rinaldi T et al. The role of interleukin-12 in immune-mediated rheumatic diseases. Reumatismo 2002;54: 11321.
  • 15
    Halse A, Tengner P, Wahren-Herlenius M, Haga H, Jonsson R. Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjogren's syndrome. Scand J Immunol 1999;49: 5338.
  • 16
    Kroneld U, Halse AK, Jonsson R, Bremell T, Tarkowski A, Carlsten H. Differential immunological aberrations in patients with primary and secondary Sjogren's syndrome. Scand J Immunol 1997;45: 698705.
  • 17
    Mustafa W, Sharafeldin A, Diab A et al. Coordinate up-regulation of the beta-chemokine subfamily in autoimmune sialoadenitis of MRL/lpr mice. Scand J Immunol 1998;48: 6238.